{
    "nct_id": "NCT04662255",
    "official_title": "A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)",
    "inclusion_criteria": "* Confirmed MCL diagnosis\n* Previously treated with at least one prior line of systemic therapy for MCL\n* Measurable disease per Lugano criteria\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Absolute neutrophil count ≥ 0.75 × 109/L without granulocyte-colony stimulating factor support within 7 days of screening\n* Hemoglobin ≥ 8 g/dL not requiring transfusion support or growth factors within 7 days of screening\n* Platelets ≥ 50 × 109/L not requiring transfusion support or growth factors within 7 days of screening.\n* AST and ALT ≤ 3.0 x upper limit of normal (ULN)\n* Total bilirubin ≤ 1.5 x ULN.\n* Creatinine clearance of ≥ 30 mL/min according to Cockcroft/Gault Formula\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an approved or investigational BTK inhibitor\n* History of bleeding diathesis\n* History of stroke or intracranial hemorrhage within 6 months of randomization\n* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified T-cell (CAR-T) therapy within 60 days of randomization\n* Clinically significant cardiovascular disease\n* Prolonged QT interval corrected using Fridericia's formula (QTcF) > 470 ms on 2/3 consecutive ECGs, and mean QTcF>470 ms on all 3 ECGs\n* Known HIV infection or active HBV, HCV, or CMV infections. (Certain participants with controlled HBV infections may still be eligible)\n* Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption\n* Ongoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment.\n* Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.\n* Vaccination with live vaccine within 28 days prior to randomization",
    "miscellaneous_criteria": ""
}